Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 5Thoracic 3Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Breast 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × WW Domain-Containing Oxidoreductase × Genitourinary × Clear all
NCT04049747 2025-03-24

IP4-CHRONOS

Imperial College London

Phase NA Completed
100 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT04239599 2022-09-29

RCT-PHART2

Sunnybrook Health Sciences Centre

Phase NA Unknown
178 enrolled
Genitourinary

Prostatic Neoplasms

NCT00064610 2008-02-11

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
102 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡